ClinicalTrials.gg
CompletedNCT01687920Updated Feb 7, 2022

Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets

A Phase 1 interventional study of BAY94-8862 (1.25mg) and BAY94-8862 (2.5mg) in Heart Failure, sponsored by Bayer. Completed at 1 site in Germany. Open to male participants aged 18 Years to 46 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-07.

Sponsored by Bayer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 46 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing finerenone in Heart Failure — 16 open to participants now, 17 under way, 8 of them phase 3. finerenone · Heart Failure.

Enrollment
23rd of 23
25 · median 120
Started
2012
the only one that year
Phase 1
2 of 23
none open now
Registered
2nd of 23
by date
Lead sponsor
8 of 23
Bayer

Among the 23 studies testing finerenone in Heart Failure, this one is the 23rd largest by enrollment, is the only one that started in 2012, is one of 2 in phase 1, and was the 2nd registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

16 of the 23 studies testing finerenone in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About finerenone

finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 46 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing finerenone in Heart Failure, or all of them as a file.
02

Study summary

This study should estimate the dose proportionality of BAY94-8862 IR tablets.

03

Conditions studied

  • Heart Failure

Keywords

  • Cardiac disorders
04

Who can participate

Ages eligible
18 Years to 46 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subject
  • Age: 18 to 46 years (inclusive) at the first screening examination
  • Ethnicity: White
  • (BMI): >= 18 and \<= 29.9 kg / m²

Exclusion criteria

Exclusion Criteria:

  • findings in the (electrocardiogram) such as a second- or third-degree AV block, prolongation of the QRS complex over 120 msec
  • Systolic blood pressure below 100 or above 140 mmHg
  • Diastolic blood pressure below 50 or above 90 mmHg
  • Heart rate below 50 or above 95 beats/ min
  • Positive results for virus surface antigen (HBsAg), virus antibodies (anti-HCV), human immune deficiency virus antibodies (anti- 1+2)
  • Participation in another clinical study during the preceding 3 months (Last Treatment from previous study to First Treatment of new study)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    BAY94-8862 (1.25mg)

    single dose BAY94-8862 IR tablet 1.25mg

    Drug: BAY94-8862 (1.25mg)

  • Experimental
    BAY94-8862 (2.5mg)

    single dose BAY94-8862 IR tablet 2.5mg

    Drug: BAY94-8862 (2.5mg)

  • Experimental
    BAY94-8862 (5mg)

    single dose BAY94-8862 IR tablet 5mg

    Drug: BAY94-8862 (5mg)

  • Experimental
    BAY94-8862 (7.5mg)

    single dose BAY94-8862 IR tablet 7.5mg

    Drug: BAY94-8862 (7.5mg)

  • Experimental
    BAY94-8862 (10mg)

    single dose BAY94-8862 IR tablet 10mg

    Drug: BAY94-8862 (10mg)

06

What researchers measure

Primary outcomes

  1. Dose proportionality of BAY94-8862 exposure in plasma when given as 1.25, 2.5, 5.0, 7.5 and 10 mg IR tablets

    Time frame: 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 15, 24, 28 & 48 h

Secondary outcomes

  1. Number of participants with adverse events as a measure of safety and tolerability of BAY94-8862

    Time frame: Up to 48 h

07

Study locations

1 site
  • CRS Clinical-Research-Services Mönchengladbach GmbH
    Mönchengladbach, Nordrhein-Westfalen 41061, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2012 to primary completion in Nov 2012, 2 months.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2012
First posted
Sep 19, 2012
StartActual
Sep 17, 2012
Primary completionActual
Nov 28, 2012
CompletionActual
Mar 21, 2013
Last update
Feb 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01687920
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 19, 2012
Start date
Sep 17, 2012
Primary completion
Nov 28, 2012
Completion
Mar 21, 2013
Last update
Feb 7, 2022

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion